Hepatitis B Alternative Medicine
Archived Posts from this Category
[An evaluation method for analysis of correlation between traditional Chinese medicine syndrome and seasonal changes of weather based on information...
Posted by admin on 16 Dec 2009 | Tagged as: Hepatitis B Alternative Medicine
Related Articles [An evaluation method for analysis of correlation between traditional Chinese medicine syndrome and seasonal changes of weather based on information entropy] Zhong Xi Yi Jie He Xue Bao. 2007 Sep;5(5):502-5 Authors: Sun JJ, Jiang J, Zhu LL, Gao YQ, Yan GL, Su SB OBJECTIVE: A method based on dubious condition of information entropy was introduced and applied to discuss a complexity problem in the analysis of correlation between traditional Chinese medicine (TCM) syndrome and season. METHODS: Eight hundred and seventy one cases of chronic virus hepatitis B (hepatitis B) with TCM clinical data were analyzed by information entropy method. RESULTS: It was found that hepatitis B with Yin deficiency of liver and kidney happened more often in summer than in other seasons. CONCLUSION: It is inferred that the difference of seasons may influence the variation of TCM syndromes. PMID: 17854548 [PubMed - indexed for MEDLINE]
Antiviral efficacy against hepatitis B virus replication of oleuropein isolated from Jasminum officinale L. var. grandiflorum.
Posted by rtrafaelmd on 16 Dec 2009 | Tagged as: Hepatitis B Alternative Medicine
Related Articles Antiviral efficacy against hepatitis B virus replication of oleuropein isolated from Jasminum officinale L. var. grandiflorum. J Ethnopharmacol. 2009 Sep 7;125(2):265-8 Authors: Zhao G, Yin Z, Dong J ETHNOPHARMACOLOGICAL RELEVANCE: Jasminum officinale L. var. grandiflorum (JOG) is a folk medicine used for the treatment of hepatitis in south of China. Phytochemical studies showed that secoiridoid glycosides are the typical constituents of this plant. AIM OF THE STUDY: The present study was undertaken to evaluate the effect of oleuropein (Ole) derived from the flowers of JOG on hepatitis B virus (HBV) replication in HepG2 2.2.15 cell line in vitro and duck hepatitis B virus (DHBV) replication in ducklings in vivo. MATERIAL AND METHODS: The extracellular hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) concentrations in cell culture medium were determined by ELISA. DHBV in duck serum was analyzed by dot blot. RESULTS: Ole blocks effectively HBsAg secretion in HepG2 2.2.15 cells in a dose-dependent manner (IC(50)=23.2 microg/ml). Ole (80 mg/kg, intraperitoneally, twice daily) also reduced viremia in DHBV-infected ducks. CONCLUSION: Ole therefore warrants further investigation as a potential therapeutic agent for HBV infection. PMID: 19580857 [PubMed - indexed for MEDLINE]
High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects.
Posted by admin on 10 Dec 2009 | Tagged as: Hepatitis B Alternative Medicine
High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2009 Dec 5; Authors: Potsch DV, Oliveira ML, Ginuíno C, Miguel JC, Oliveira SA, Silva EF, Moreira RB, Cruz GV, Oliveira AL, Camacho LA, Barroso PF We evaluated a modified HBV regimen in a cohort of HIV-infected subjects in Rio de Janeiro, Brazil. HIV-infected subjects with no serologic evidences of previous hepatitis B infection were immunized with 4 doses (40mug each) of recombinant hepatitis B vaccine given at 0, 1, 2 and 6 months. Blood samples were collected 1 month after the last dose and anti-HBs titers were measured. A protective antibody response was defined as an anti-HBs titer >/=10mUI/mL. Forty-seven subjects (30 women, 17 men; mean age was 36 years, ranging from 21 to 58 years) were included in the final analysis. Median baseline CD4+ lymphocyte count was 402cells/mm(3) and 33 subjects (70%) had an HIV viral load below 80copies/mL. A protective antibody response was observed in 42 (89%) subjects. Thirty-seven (78%) and 28 (60%) patients developed anti-HBs titers higher than 100mUI/mL and 1000mUI/mL, respectively. 1 out of 5 non-responders (20%) had an HIV viral load below the detection limit, in contrast with 32 (76%) of those with an adequate serologic response (p=0.02). These findings suggest that 4-double dose alternative schedule may be considered to overcome the lower seroconversion rates observed with the standard regimens in HIV-infected subjects. PMID: 19995540 [PubMed - as supplied by publisher]
Continued here:
High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects.
Bortezomib Inhibits Hepatitis B Virus Replication in Transgenic Mice.
Posted by rtrafaelmd on 02 Dec 2009 | Tagged as: Hepatitis B Alternative Medicine
Bortezomib Inhibits Hepatitis B Virus Replication in Transgenic Mice. Antimicrob Agents Chemother. 2009 Nov 30; Authors: Bandi P, Garcia ML, Booth CJ, Chisari FV, Robek MD Pharmacological modulation of cellular proteins as a means to block virus replication has been proposed as an alternative antiviral strategy that may be less susceptible to the development of viral drug-resistance. Recent evidence indicates the ubiquitin-proteasome pathway interacts with different aspects of the HBV life cycle in cell culture models of virus replication. We therefore examined the effect of proteasome inhibition on HBV replication in vivo using HBV transgenic mice. The proteasome inhibitor bortezomib (VELCADE(R)) inhibits proteasome activity in vivo, and is used therapeutically for the clinical treatment of multiple myeloma. We found that a single intravenous dose of 1 mg/kg bortezomib reduced virus replication for up to 6 days. The inhibition of HBV by bortezomib was dose-dependent, and occurred at a step in replication subsequent to viral RNA and protein expression. The reduction in HBV replication did not result from non-specific hepatocellular toxicity, and was not mediated indirectly through the induction of an intrahepatic interferon response. Thus, pharmacological manipulation of the ubiquitin-proteasome pathway may represent an alternative therapeutic approach for the treatment of chronic HBV infection. PMID: 19949053 [PubMed - as supplied by publisher]
Read more here:
Bortezomib Inhibits Hepatitis B Virus Replication in Transgenic Mice.
Evaluation on quality of life and analysis on its correlation with TCM syndromes in patients of chronic hepatitis B.
Posted by admin on 17 Nov 2009 | Tagged as: Hepatitis B Alternative Medicine
Related Articles Evaluation on quality of life and analysis on its correlation with TCM syndromes in patients of chronic hepatitis B. Chin J Integr Med. 2009 Feb;15(1):30-3 Authors: Zhang W, Wang LQ, Liu YB OBJECTIVE: To evaluate the quality of life (QOL) in patients with chronic hepatitis B (CHB) and analyze its correlation with traditional Chinese medicine (TCM) syndrome types. METHODS: With cross-sectional investigation adopted, the QOL of 335 CHB patients was studied by the World Health Organization Quality of Life BREF Questionnaire (WHOQOL-BREF) and the chronic liver disease questionnaire (CLDQ). The results was compared with that of 30 healthy persons. RESULTS: The QOL of the patients with chronic hepatitis B was lower than the healthy persons with signififi cant difference between them (P<0.01). Also it was different in patients of different TCM syndrome types (P<0.05 or P<0.01). The lowest QOL was shown in patients of the blood-stasis blocking vessel type and Gan ()-stagnation with Pi ()-defificiency type (P<0.01). CONCLUSION: The QOL of CHB patients is lower than of healthy persons and closely correlated with TCM syndrome types. PMID: 19271167 [PubMed - indexed for MEDLINE]
View original here:
Evaluation on quality of life and analysis on its correlation with TCM syndromes in patients of chronic hepatitis B.
Influence of TCM therapy for supplementing Pi and nourishing Shen on dendritic cell function in patients with chronic hepatitis B treated by…
Posted by admin on 17 Nov 2009 | Tagged as: Hepatitis B Alternative Medicine
Related Articles Influence of TCM therapy for supplementing Pi and nourishing Shen on dendritic cell function in patients with chronic hepatitis B treated by lamivudine. Chin J Integr Med. 2009 Feb;15(1):60-2 Authors: Zhang YH, Liu YH OBJECTIVE: To observe the influence of traditional Chinese medicine (TCM) therapy for supplementing Pi () and nourishing Shen (, SPNS) on dendritic cell function in patients with chronic hepatitis B (CHB) treated by lamivudine. METHODS: Sixty CHB patients with positive HBeAg were equally randomized by digital table into two groups: the observation group and the control group. Patients in the control group were treated with lamivudine only, while patients in the observation group were treated with lamivudine combined with SPNS fomula, for 12 weeks. The phenotype and function of dendritic cell, as well as its secretion factor interleukin 12 (IL-12) in all patients were determined after termination of therapy and the impacts on alanine transaminase (ALT) and HBVDNA were observed. RESULTS: The phenotypes of dendritic cells such as CD1a, CD80, CD86, human leukocyte antigen (HLA-DR) and intercellular adhesion molecule-1, as well as the levels of stimulation index (SI) and IL-12 were higher in the observation group than those in the control group (P<0.05 or P<0.01). Meanwhile, signififi cant difference between the two groups was also shown in the normalizing rates of ALT and HBV-DNA (P<0.05). CONCLUSION: TCM therapy for SPNS can signifificantly improve the function of dendritic cells in patients with CHB treated by lamivudine and enhance the early stage response of patients to the treatment. PMID: 19271172 [PubMed - indexed for MEDLINE]
Read the original:
Influence of TCM therapy for supplementing Pi and nourishing Shen on dendritic cell function in patients with chronic hepatitis B treated by…
Hot topics in Chinese herbal drugs research documented in PubMed/MEDLINE by authors inside China and outside of China in the past 10 years: based on…
Posted by admin on 21 Oct 2009 | Tagged as: Hepatitis B Alternative Medicine
Related Articles Hot topics in Chinese herbal drugs research documented in PubMed/MEDLINE by authors inside China and outside of China in the past 10 years: based on co-word cluster analysis. J Altern Complement Med. 2009 Jul;15(7):779-85 Authors: Li HY, Cui L, Cui M OBJECTIVE: This study aims to gain an overview of hot topics related to research focused on Chinese herbal drugs by authors inside China and outside of China in the past 10 years. METHODS: PubMed/MEDLINE was utilized in order to investigate and select research that was published on “Chinese herbal drugs” from 1998 to 2007, by authors located both inside and outside of China (MeSH terms were downloaded and ranked). MeSH terms that frequently appeared were identified and co-word analysis was carried out for two groups: (1) authors located in China, and (2) authors based outside of China, respectively. The hot topics concerning research into Chinese herbal drugs were concluded after cluster analysis and related document analysis. RESULTS: For authors in the China group versus those outside the China group, the search results were 4790 versus 2609 citations and approximately 40,000 versus 20,000 MeSH terms, respectively. The threshold value of highly frequent terms was set at 30 versus 20, and the cumulative frequency percentage of these terms was 40.92% versus 36.67%, respectively. Thus, 43 highly frequent MeSH terms were identified and 43 x 43 co-word matrices were acquired for each group. The appearance frequency of MeSH showed that most research focused on pharmacology, therapeutic application, phytotherapy, side-effects of Chinese herbal drugs, and identification of active chemical components in herbs. CONCLUSION: The hot topics are as follows: (1) anti-inflammatory activity, antioxidant activities, anticancer activity of phytogenic antineoplastic agents, and neuroprotective effects of Chinese herbal drugs; (2) common diseases treated with Chinese herbal drugs include hepatocirrhosis, diabetes, angina, chronic hepatitis B in China, and diabetes, asthma, prostate cancer, and hepatocirrhosis outside of China; (3) Chinese herbal nephropathy and acute hepatitis induced by Chinese herbal drugs; (4) PC-SPES (PDQ) for the treatment of prostate cancer, which was a hot topic for researchers located outside of China; (5) research on extraction of active components from medicinal plants; and finally (6) research related to the identification of the Chinese herbal drugs component with state-of-the-art technologies in China. PMID: 19534611 [PubMed - indexed for MEDLINE]
See the original post here:
Hot topics in Chinese herbal drugs research documented in PubMed/MEDLINE by authors inside China and outside of China in the past 10 years: based on…
Hepatocellular Carcinoma in Keio Affiliated Hospitals – Diagnosis, Treatment, and Prognosis of this Disease -.
Posted by rtrafaelmd on 15 Oct 2009 | Tagged as: Hepatitis B Alternative Medicine
Hepatocellular Carcinoma in Keio Affiliated Hospitals – Diagnosis, Treatment, and Prognosis of this Disease -. Keio J Med. 2009 Sep;58(3):161-75 Authors: Saito H, Masuda T, Tada S, Ebinuma H, Yamagishi Y, Ojiro K, Inoue M, Hibi T We have retrospectively investigated patients with hepatocellular carcinoma (HCC) (912 cases) treated in the Affiliated Hospitals of Keio University (the Keio Association for the Study of Liver Diseases: KASLD) and here we review the recent diagnosis and treatment of HCC. HCC is a major cause of death in Japan and a major etiology of this disease is chronic viral infection such as hepatitis C virus (HCV) and hepatitis B virus (HBV). Screening of HCC by imaging studies and measurement of serum tumor markers successfully prolonged survival of the patients in Japan. The prognosis of this disease has been determined by both tumor factors and degree of liver function, and its staging is usually established with a recent system such as Japan Integrated Staging Score (JIS). The 5-year survival rate of JIS stage 0, 1, 2 and 3 were 68.3%, 51.9%, 25.8% and 16.6%, respectively in our cohort. Multivariate analysis using Cox proportional hazard models showed that age (>65) , HCV infection, tumor number, TB (>1.0), AFP (>20) and PIVKA-II (>40) were significant factors affecting survival among the entire patients. Major treatment strategies are hepatic resection, radio frequency ablation and transarterial chemo-embolization, but alternative treatments such as radiation, chemotherapy, and their combination have been used to reduce tumor sizes resulting prolongation of the survival or maintenance of patients’ quality of life, while liver transplantation has not been popular in Japan. However, the overall survival continues to decrease from year to year, and does not show a plateau phase in Kaplan-Mayer curve. These results suggest that the best way to improve survival can be achieved by prevention of the disease. Antiviral therapies have decreased the incidence of HCC, indicating that treatment for chronic hepatitis is the best way to prevent HCC development at present. PMID: 19826210 [PubMed - in process]
Original post:
Hepatocellular Carcinoma in Keio Affiliated Hospitals – Diagnosis, Treatment, and Prognosis of this Disease -.
Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication.
Posted by rtrafaelmd on 13 Oct 2009 | Tagged as: Hepatitis B Alternative Medicine
Related Articles Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication. J Ethnopharmacol. 2009 Jul 15;124(2):189-96 Authors: Kim HJ, Yoo HS, Kim JC, Park CS, Choi MS, Kim M, Choi H, Min JS, Kim YS, Yoon SW, Ahn JK ETHNOPHARMACOLOGICAL RELEVANCE: A medicinal herb Curcuma longa Linn has been used for treating various liver diseases caused by hepatitis B virus (HBV) in Asia. AIM OF THE STUDY: The study was performed in order to investigate the antiviral activity of Curcuma longa Linn against HBV replication in liver cells. MATERIALS AND METHODS: Aqueous extract of Curcuma longa Linn (CLL) was prepared and used to analyze its antiviral activity against HBV replication in HepG 2.2.15 cells, which contain HBV genomes. The inhibitory effect of CLL on HBV replication was examined by testing the levels of secreted HBV surface antigens (HBsAg), HBV DNAs, and HBV RNAs in HepG 2.2.15 cells using ELISA, Southern blot, and Northern blot analyses. Cytotoxic activities of CLL extract on various liver cells were analyzed by MTT assay. To dissect the inhibitory mechanism of CLL extract on HBV replication, the levels of p53 protein and p53 mRNAs were analyzed by Western blot and RT-PCR in HepG 2.2.15 cells. The repression of CLL extract on HBV transcription was analyzed by RT-PCR and CAT assay. RESULTS: CLL extract repressed the secretion of HBsAg from HepG 2.2.15 cells. CLL extract also suppressed the production of HBV particles and the level of intracellular HBV RNAs in HepG 2.2.15 cells, suggesting that CLL extract inhibits HBV replication. We found that the anti-HBV activity of CLL extract is mediated through enhancing the cellular accumulation of p53 protein by transactivating the transcription of p53 gene as well as increasing the stability of p53 protein. It turned out that CLL extract repressed the transcription of HBx gene by suppressing HBV enhancer I and X promoter through p53 protein. In addition, CLL extract did not have any cytotoxic effects on liver cells. CONCLUSION: These data showed that CLL extract represses HBV replication through enhancing the level of p53 protein. CLL extract can be used as a safe and specific drug for patients with liver diseases caused by HBV infection. PMID: 19409970 [PubMed - indexed for MEDLINE]
Read more here:
Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication.
Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen.
Posted by admin on 13 Oct 2009 | Tagged as: Hepatitis B Alternative Medicine
Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen. Vaccine. 2009 Oct 7; Authors: Wieland A, Riedl P, Reimann J, Schirmbeck R Immunodominance hierarchies operating in immune responses to viral antigens limit the diversity of the elicited T cell responses. The L(d)/S(28-39)-restricted CD8 T cell response to the hepatitis B surface antigen (HBsAg or S) prevents copriming of D(d)- and K(b)-restricted CD8 T cell responses. We exchanged L to V at position S(39) of HBsAg to construct mutant S(L39V). Comparable levels of wild-type S and mutant S(L39V) were produced by transiently transfected cells, and mice immunized with the pCI/S and pCI/S(L39V) DNA vaccines showed comparable serum antibody responses to HBsAg. The pCI/S but not pCI/S(L39V) DNA vaccination induced L(d)/S(28-39)-specific CD8 T cell responses. However, the pCI/S(L39V) DNA vaccine efficiently primed CD8 T cell responses to the subdominant D(d)- and K(b)-restricted epitopes, confirming the immunosuppressive phenotype of the L(d)/S(28-39)-specific CD8 T cell response. A single point mutation within the HBsAg can hence completely silence a ‘dominant’ CD8 T cell response thereby facilitating priming of a multispecificrepertoire of suppressed, ‘subdominant’ epitopes. The data have practical implications for understanding HBV-specific CD8 T cell responses and for the design of novel vaccination strategies. PMID: 19818719 [PubMed - as supplied by publisher]
Read the original here:
Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen.
